A Real-Life One-Year Non-Interventional Study Assessing Safety, Tolerability, and Treatment Outcome of the SQ HDM SLIT-Tablet (Acarizax^®) in House Dust Mite Allergic Rhinitis With or Without Asthma.

ABSTRACT:

Introduction

The aim of this study was to investigate the safety profile, tolerability, and outcome of the SQ^® house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet after 1 year of treatment in clinical practice among adults with HDM-related allergic rhinitis (AR) ± allergic asthma (AA).

Methods

In a non-interventional multicenter, observational study, patients were followed at 3 visits for 1 year. Adverse events (AE) were recorded at all visits. Patients graded their allergic symptoms as none, mild, moderate, or severe, and recorded AR and AA medication use. Asthma symptom control was assessed according to the Global Initiative for Asthma (GINA).

Results

One hundred and ninety-eight patients were included; 115 (58%) had AR without asthma and 83 (42%

SUBMITTER: Sidenius K 

PROVIDER: S-EPMC8137770 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature